FULC

NASDAQ Healthcare

Fulcrum Therapeutics, Inc. - Common Stock

Biotechnology

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

๐Ÿ“Š Market Data
๐ŸŽฏ Investment Strategy Scores

FULC scores across each investment strategy. Higher is better for that strategy's goals.

High dividend yield + low volatility
๐Ÿš€ Moon Shot 99/100โ€” 0
High growth potential (high beta + oversold)
๐Ÿ”ช Falling Knife 85/100โ–ผ -5
Contrarian plays (oversold + below moving average)
๐ŸŽˆ Over-Hyped 23/100โ–ฒ +6
Overbought stocks (potential short candidates)
Large-cap, institutional-quality stocks
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿš€ Moon Shot (99/100) โ€” this strategy High growth potential (high beta + oversold).

Lowest fit among scored strategies: ๐Ÿ’ฐ Dividend Daddy (1/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find FULC in your text

Paste any article, transcript, or post โ€” the tool will extract FULC and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.